Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: William Partmann who wrote (791)	12/25/1999 9:59:00 AM
From: Gary Korn	Read Replies (1) \| Respond to of 10345

12/24/99 Reg. News Serv. (Pg. Unavail. Online) 1999 WL 31187679 Regulatory News Service Copyright (C) 1999 Regulatory News Service; Source: World Reporter (TM) Friday, December 24, 1999 Elan Corporation PLC - Further re Acqn of Interest ELAN CONFIRMS ARRANGEMENTS FOR THE PURCHASE OF AXOGEN LIMITED DUBLIN, IRELAND, December 23, 1999 -- Elan Corporation, plc (NYSE: ELN) ("Elan") has confirmed the arrangements for the purchase of all of the outstanding common shares of Axogen Limited (AMEX: AXG) ("Axogen") at a price of $34.56 per share payable in cash which was announced on November 29, 1999. Instructions and letters of transmittal have been sent to all shareholders by the paying agent, The Bank of New York, and the transaction will close on December 31, 1999. Payment will be made by Bank of New York on that date for all transmittal letters and share certificates received before that date. Axogen shares will cease to trade on the American Stock Exchange on that date. Elan is a leading worldwide specialty pharmaceutical company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan shares trade on the New York, London and Dublin Stock Exchanges. Contact: (US) Mary Bingham Director - Investor Relations Elan Corporation, plc Ph: 212-407-5740 800-252-3526 email: mansaldi@elancorp.com (Europe) Emer Reynolds Director, Investor Relations Elan Corporation, plc Ph: 353-1-709-4080 00800 28352600 email: ereynolds@elancorp.com 23 December, 1999 ---- INDEX REFERENCES ---- COMPANY (TICKER): Axogen Ltd.; Axogen Ltd.; Bank of New York Co. (AXG U.AXG BK)